首页> The oncologist> A phase I/II trial of avelumab combinations with ivuxolimab, utomilumab, and radiation therapy in patients with advanced gastrointestinal malignancies.

A phase I/II trial of avelumab combinations with ivuxolimab, utomilumab, and radiation therapy in patients with advanced gastrointestinal malignancies.

导出 OA

翻译打印收藏纠错

第一作者： Jibran,Ahmed

第一单位： Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.

作者： Jibran,Ahmed ^[1] ; Anne,Knisely ^[2] ; Carlos,Torrado ^[1] ; Bettzy,Stephen ^[1] ; Yali,Yang ^[1] ; Juhee,Song ^[3] ; Anas,Alshawa ^[1] ; Abdulrazzak,Zarifa ^[1] ; Anuja,Jhingran ^[4] ; Eugene J,Koay ^[4] ; Van Karlyle,Morris ^[5] ; Milind,Javle ^[5] ; Robert A,Wolff ^[5] ; Funda,Meric-Bernstam ^[1] ; Shubham,Pant ^[5] ; Jordi,Rodon ^[1] ; Aung,Naing ^[1]

作者单位： Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States. ^[1] Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77230, United States. ^[2] Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States. ^[3] Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States. ^[4] Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States. ^[5]

关键词 4-IBB OX40 PD-L1 avelumab colorectal gastric immunotherapy ivuxolimab liver pancreatic utomilumab